Is this randomised evidence?

No. It is observational data analysed using target trial emulation, which removes design-induced biases but cannot balance unmeasured factors.

Why not just run a randomised trial?

Cardiovascular and kidney outcomes accumulate over years, requiring very large, very long and very expensive trials.

Does it replace the randomised outcome trials?

No. Those remain stronger for the specific compounds they studied. Emulation covers broader populations at lower evidential weight.

Research & Regulatory News

What the Cardiovascular and Kidney Data Actually Is

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-232 cited sources

Tang and colleagues examined cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity using target trial emulation, published in Diabetes, Obesity and Metabolism in November 2025. It is observational data analysed with trial-like discipline, not a randomised trial.

Key facts

Study: Tang 2025, Diabetes Obes Metab (PMID 40874398)
Design: Target trial emulation
Data source: Observational records
Population: Adults with obesity
Outcomes: Cardiovascular and kidney
Randomised: No

Why this question needed a method like this

Cardiovascular and kidney outcomes accumulate over years. A randomised trial powered to detect differences in them requires very large numbers followed for a long time, at enormous cost. Emulation applied to existing records offers an earlier reading, and that is why this design is appearing across the incretin literature.

What the design permits

A comparison constructed to avoid the biases that arise from analytical choices — immortal time, prevalent user selection, misaligned follow-up. Where the target trial is specified in advance and time zero is properly aligned, the result is substantially more trustworthy than a conventional retrospective analysis.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

What it does not permit

Causal certainty. People prescribed a GLP-1 receptor agonist differ from those not prescribed one in ways records capture only partly — health engagement, access, unmeasured severity, concurrent care. Those differences remain in the comparison, and no design applied after the fact removes them.

How this sits beside the randomised evidence

Randomised cardiovascular outcome trials exist for individual incretins and remain the stronger evidence for those specific compounds. Emulation studies cover broader populations and longer follow-up than trials manage, at lower evidential weight. Both are useful and they are not interchangeable, which is the distinction most reporting collapses.

The parallel finding in heart failure

Lin and colleagues applied the same approach to tirzepatide in heart failure with preserved ejection fraction, published in Nature Communications in May 2025. Two independent emulation studies on incretin outcomes in one year indicates the method is becoming standard for these questions rather than exceptional.

What none of it concerns

Research material. These studies examine licensed medicines prescribed and monitored clinically, in defined patient populations. Nothing supplied here is a GLP-1 receptor agonist, is covered by these findings, or is an alternative to a prescribed medicine.

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is this randomised evidence?: No. It is observational data analysed using target trial emulation, which removes design-induced biases but cannot balance unmeasured factors.
Why not just run a randomised trial?: Cardiovascular and kidney outcomes accumulate over years, requiring very large, very long and very expensive trials.
Does it replace the randomised outcome trials?: No. Those remain stronger for the specific compounds they studied. Emulation covers broader populations at lower evidential weight.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum